An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
about
Tegaserod for the treatment of irritable bowel syndrome and chronic constipationTegaserod for the treatment of irritable bowel syndromeConducting multinational, cross-cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team reportAbdominal bloating: pathophysiology and treatmentThe effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.Tegaserod for constipation-predominant irritable bowel syndrome.Review article: the treatment of functional abdominal bloating and distension.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.Studying sex and gender differences in pain and analgesia: a consensus report.The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipationRecent advances in pharmacological treatment of irritable bowel syndrome.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeEffect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study.Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.The treatment of irritable bowel syndromePromotility medications--now and in the future.What Is New in Rome IV.Treating irritable bowel syndrome: overview, perspective and future therapies.Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.Tegaserod and IBS: a perfect match?Pharmacology of serotonin: what a clinician should know.A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipationSystematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials.Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.Tegaserod-induced myocardial infarction: case report and hypothesis.Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom.Review of tegaserod in the treatment of irritable bowel syndrome.Review article: tegaserod -- the global experience.Review article: tegaserod for chronic constipation.Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders.Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders.Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.Emerging drugs for irritable bowel syndrome.Drugs acting on serotonin receptors for the treatment of functional GI disorders.
P2860
Q24242922-3AF32C65-DAFC-44C1-9435-CAFC4F466EBFQ24247426-5161C4B9-9151-429B-A3AA-DF19CB618CA3Q26827089-4E9CA790-FD48-4232-A203-D589F559FFE0Q26851622-75322966-22CF-4E4E-ADCA-9BE6FC46AB36Q33431815-790E910D-BD27-427A-A03D-88CAD5CBE658Q33436477-287FF605-2AC6-4509-B6B4-7910B62D888CQ33450132-D0CDBF7E-6C88-437E-B554-0E4D7C461B2AQ33451900-DE69A7EB-A2BE-43BE-840F-E7E0176B6CC3Q33452721-6B9EB92E-C1D0-4DEF-9B8B-6EB72EE76D2BQ33456102-B7C1740A-D477-4FC8-9944-BCA8CC952EC6Q33470528-796A3B29-9C40-424E-A40B-C973B969CDAAQ33661852-073A3B4D-A57D-4FD0-9FC0-BBDC2DCD1BD9Q33890463-F4260A77-B1BB-41C4-A25E-3139206A8412Q33958853-176023E2-58E9-4EFE-8F3B-8F3D157F6836Q34345704-AF09117A-2D5D-4688-9F78-5E82B4685C1FQ34378514-223DB39E-9847-4B7A-AF53-1ABD58753413Q34394157-82375429-4F3F-4FBA-B40A-B644192BCBE9Q34409009-22BA07FA-34B7-480A-8763-8E8CCB6D5ACDQ34548916-FCFA1D58-FFE3-4398-8DAD-A9E6B965A64FQ34680985-E4E09E20-B7FC-4634-81E8-F1F0D5EA930CQ35047051-91578EAA-60B7-4117-9F1A-8E52F6214477Q35586987-4F934B9C-4B56-4542-9FBD-01A841C81EB6Q35595588-F0C5B60C-CAF8-432C-8936-407F14EBCBA5Q35596862-2433B6D4-277E-4AB4-A830-32A4387024A7Q35597981-BD3E170B-C290-4707-9CDF-A5A6D1FEB94FQ35675791-FA3B80CF-F849-4A21-96BB-641E3DB7A338Q35691226-DEBEF928-7987-4FBC-8382-1100BC81017DQ35746810-CB4AB377-0EBB-4364-A340-8B9ED900D882Q35751537-0EBE5640-6477-4222-936A-C05A7FC37C5FQ35919167-6E080714-B512-4F74-8C19-144859BC9305Q35925555-ED27461A-40F1-4BD8-AF18-7FC1F1AEF999Q35936942-D652EB9A-77BC-4997-9623-7C79FBB11877Q35936947-9CD78448-FA6B-4A88-A47F-BC16DC98C6F9Q35985391-77E791A2-ED5A-4C0E-AA70-D2ACAA3AC027Q36072575-9D4D9C26-DB5B-4D0A-B143-13A065297E4CQ36217916-30E74994-E19F-4C81-8CEF-043BD01B3082Q36404927-A61DC8E3-E792-4282-B276-11B5784DD37FQ36435902-80E0CF32-B1A2-43F4-9EE4-931116A51AFCQ36458417-83CF665C-BB07-414F-B150-9F6EDB339FD0Q36478089-DBAC3883-17FE-4A73-880A-1E462BDA2749
P2860
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@ast
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@en
type
label
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@ast
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@en
prefLabel
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@ast
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@en
P2093
P2860
P356
P1433
P1476
An Asia-Pacific, double blind, ...... with irritable bowel syndrome.
@en
P2093
M Z Mazlam
S Thongsawat
P2860
P304
P356
10.1136/GUT.52.5.671
P407
P577
2003-05-01T00:00:00Z